NGMedical GmbH Announces First Case of Its BEE PLIF in the USA

NGMedical, a German medical device manufacturer exclusively focused on creating innovative technologies for spinal applications announces the first USA implantation of its purely additively manufactured titanium BEE® PLIF.

The case was performed on February 18th, 2022 by Jonathan A. Tuttle, MD at University Hospital in Augusta, GA.

“The BEE® PLIF implant system represents a refinement of details that matter.  The instruments are elegant and intuitive, and the implant is refined in structure and anatomical design.  I’m pleased to incorporate BEE® PLIF into my armamentarium of surgical solutions for my patients,” said Dr. Tuttle.

Mitch White, President of NGMedical, Inc. added, “I’m excited and honored Dr. Tuttle was the first US surgeon to implant BEE® PLIF, but I’m not surprised.  Dr. Tuttle had a discerning appreciation for the BEE® PLIF’s evolutionary design, and was anxious for BEE® as a surgical option. This promises to be a year of rapid growth as we introduce the inimitable BEE® platform of interbody implants across the country.”

“This successful market launch in the USA is an important step for NGMedical. The first operation with the BEE® PLIF cage in this important market is a great milestone in our international commercialization. We look forward to expanding our portfolio and footprint in the USA.” says Peter Weiland, CEO of NGMedical.

NG Medical notes the BEE® PLIF cage is another significant innovation from the team who invented the first line of additively manufactured interbody devices. The purposefully designed honeycomb endplate design reduces the risk of subsidence, while allowing fusion. The honeycomb structure allows for bony ingrowth while offering a very large graft space. Smooth lateral surfaces facilitate insert and rotate technique. BEE® PLIF is offered in a wide range of sizes up to 18° lordosis.

SourceNGMedical

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”